Balcom Alexandra 4
4 · Nuvalent, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Nuvalent (NUVL) CFO Alexandra Balcom Sells Shares, Exercises Options
What Happened
Alexandra Balcom, CFO of Nuvalent, exercised 11,430 option-based shares on March 24, 2026 (exercise price $1.08; cost $12,344) and sold a total of 25,130 shares in open-market transactions on March 24–25, 2026, generating approximately $2.47 million in gross proceeds. The filing shows the 11,430 exercised shares were also recorded as disposed at $0.00 as part of the same reporting entry (see Key Details for notes).
Key Details
- Primary dates: March 24–25, 2026. Form 4 filed March 26, 2026.
- Sales (open market): 2,599 shares @ weighted avg $95.03 = $246,983; 7,671 shares @ weighted avg $95.88 = $735,495; 1,160 shares @ weighted avg $96.50 = $111,940; 13,700 shares @ weighted avg $100.16 = $1,372,192. Total sales proceeds ≈ $2,466,610.
- Option exercise: 11,430 shares acquired at $1.08 per share (total cost $12,344). The same 11,430 shares also appear as disposed at $0.00 in the filing (reported as a derivative disposition).
- Footnotes: Transactions were effected under a Rule 10b5-1 trading plan adopted Dec 23, 2025 (F1). Reported sale prices are weighted averages across multiple trades with price ranges: $94.34–95.33 (F2), $95.35–96.34 (F3), $96.35–96.72 (F4), $100.00–100.61 (F5). The exercised options are fully vested (F6).
- Shares owned after the transactions: not specified in the provided filing data.
- Timeliness: Form 4 was filed March 26, 2026 covering trades on March 24–25; filing was submitted within the typical two-business-day window.
Context
The filing shows an exercise of vested options followed by open-market sales executed under a pre-established 10b5-1 plan. The notation of the exercised shares as disposed at $0.00 likely reflects internal option-settlement or reporting mechanics rather than an open-market sale of those particular shares; the cash proceeds reported come from the separate open-market sales lines. These are routine insider transactions (sales under a trading plan) and are factual disclosures of holdings and transactions rather than statements of intent or company outlook.
Insider Transaction Report
- Exercise/Conversion
Class A Common Stock
[F1]2026-03-24$1.08/sh+11,430$12,344→ 110,663 total - Sale
Class A Common Stock
[F1][F2]2026-03-24$95.03/sh−2,599$246,983→ 108,064 total - Sale
Class A Common Stock
[F1][F3]2026-03-24$95.88/sh−7,671$735,495→ 100,393 total - Sale
Class A Common Stock
[F1][F4]2026-03-24$96.50/sh−1,160$111,940→ 99,233 total - Sale
Class A Common Stock
[F1][F5]2026-03-25$100.16/sh−13,700$1,372,192→ 85,533 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-03-24−11,430→ 150,226 totalExercise: $1.08Exp: 2031-02-16→ Class A Common Stock (11,430 underlying)
Footnotes (6)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.34 to $95.33, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) of this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.35 to $96.34, inclusive.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.35 to $96.72, inclusive.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.61, inclusive.
- [F6]The shares underlying this option are fully vested.